Perspective from Richard J. Duffey, MD
Source:

Reinstein DZ, et al. J Refract Surg. 2015;doi:10.3928/1081597X-20150423-05.

June 19, 2015
1 min read
Save

Mel 90 excimer laser for myopic LASIK yields predictable outcomes

Perspective from Richard J. Duffey, MD
Source:

Reinstein DZ, et al. J Refract Surg. 2015;doi:10.3928/1081597X-20150423-05.

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

An updated excimer laser with a faster pulse rate and new ablation profile delivered predictable refractive outcomes in myopic LASIK, according to a study.

The retrospective study included 286 eyes of 147 patients who underwent myopic LASIK with the Mel 90 excimer laser and VisuMax femtosecond laser (both Carl Zeiss Meditec). The Mel 90 laser, an upgrade of the Mel 80 platform, can be operated with a pulse rate of 250 Hz or 500 Hz. It features the Triple-A ablation profile for low and high myopic corrections.

Patients with preoperative spherical equivalent refraction up to –10.38 D, cylinder up to 5 D and corrected distance visual acuity of 20/25 or better were included. There were no nomogram adjustments. Patients were followed for 3 months.

Mean preoperative spherical equivalent refraction was –3.83 D, and mean preoperative cylinder was –0.94 D. Preoperative corrected distance visual acuity was 20/20 or better in 97% of eyes.

Mean predictability of spherical equivalent refraction was –0.13 D. Postoperative spherical equivalent refraction was 0.5 D in 88% of eyes and 1 D in 100% of eyes.

Postoperative uncorrected distance visual acuity was 20/20 or better in 92% of eyes and 20/25 or better in 99% of eyes.

One line of corrected distance visual acuity was lost in 6% of eyes; no eyes lost two or more lines.

Mesopic contrast sensitivity improved significantly at 3 and 18 cycles per degree (P = .021 and P ≤ .001, respectively). – by Matt Hasson

Disclosure: Reinstein reports he is a consultant for Carl Zeiss Meditec and has a proprietary interest in Artemis technology (ArcScan). The other authors report no relevant financial disclosures.